SLC12A5 and epilepsy: This author evaluated the expression of NKCC1 and KCC2 in an animal model of epilepsy and found that the PTZ (pentylenetetrazol) group treated with KD presented an overexpression of KCC2, and a reduction in the expression of NKCC1.